NASDAQ:OTIC - Otonomy Stock Price, Price Target & More

$3.80 0.00 (0.00 %)
(As of 04/20/2018 12:06 PM ET)
Previous Close$3.80
Today's Range$3.75 - $3.85
52-Week Range$2.80 - $21.15
Volume45,389 shs
Average Volume429,105 shs
Market Capitalization$120.78 million
P/E Ratio-1.28
Dividend YieldN/A
Beta3.13

About Otonomy (NASDAQ:OTIC)

Otonomy logoOtonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200

Debt

Debt-to-Equity RatioN/A
Current Ratio14.95%
Quick Ratio14.95%

Price-To-Earnings

Trailing P/E Ratio-1.28
Forward P/E Ratio-2.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.24 million
Price / Sales93.71
Cash FlowN/A
Price / CashN/A
Book Value$3.87 per share
Price / Book0.98

Profitability

EPS (Most Recent Fiscal Year)($2.97)
Net Income$-90,130,000.00
Net Margins-7,292.07%
Return on Equity-63.35%
Return on Assets-58.51%

Miscellaneous

Employees53
Outstanding Shares30,580,000

How to Become a New Pot Stock Millionaire

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How were Otonomy's earnings last quarter?

Otonomy (NASDAQ:OTIC) announced its earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company earned $0.27 million during the quarter, compared to the consensus estimate of $0.46 million. Otonomy had a negative net margin of 7,292.07% and a negative return on equity of 63.35%. Otonomy's revenue for the quarter was down 1.1% on a year-over-year basis. View Otonomy's Earnings History.

When is Otonomy's next earnings date?

Otonomy is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Otonomy.

What price target have analysts set for OTIC?

4 brokers have issued 12 month target prices for Otonomy's shares. Their forecasts range from $8.00 to $15.00. On average, they anticipate Otonomy's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Otonomy.

Who are some of Otonomy's key competitors?

Who are Otonomy's key executives?

Otonomy's management team includes the folowing people:
  • Dr. Jay B. Lichter, Co-Founder & Chairman (Age 56)
  • Dr. David Allen Weber, Pres, CEO & Director (Age 58)
  • Mr. Paul E. Cayer, Chief Financial & Bus. Officer and Principal Accounting Officer (Age 56)
  • Dr. Dean Hakanson, Consultant (Age 66)
  • Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel

Has Otonomy been receiving favorable news coverage?

Media headlines about OTIC stock have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Otonomy earned a coverage optimism score of 0.04 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.33 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $3.80.

How big of a company is Otonomy?

Otonomy has a market capitalization of $120.78 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]


MarketBeat Community Rating for Otonomy (OTIC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  308
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Otonomy (NASDAQ:OTIC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Otonomy in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 163.16%. The high price target for OTIC is $15.00 and the low price target for OTIC is $8.00. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$10.00$10.00
Price Target Upside: 163.16% upside98.02% upside93.24% upside177.78% upside

Otonomy (NASDAQ:OTIC) Consensus Price Target History

Price Target History for Otonomy (NASDAQ:OTIC)

Otonomy (NASDAQ:OTIC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018JPMorgan ChaseDowngradeNeutral -> UnderweightHighView Rating Details
3/12/2018Piper JaffrayUpgradeNeutral -> OverweightMediumView Rating Details
8/31/2017CowenReiterated RatingOutperform$55.00 -> $9.00LowView Rating Details
8/31/2017SunTrust BanksReiterated RatingBuy$45.00 -> $15.00HighView Rating Details
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Otonomy (NASDAQ:OTIC) Earnings History and Estimates Chart

Earnings by Quarter for Otonomy (NASDAQ:OTIC)

Otonomy (NASDAQ:OTIC) Earnings Estimates

2018 EPS Consensus Estimate: ($3.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.74)($0.74)($0.74)
Q2 20181($0.78)($0.78)($0.78)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.81)($0.81)($0.81)

Otonomy (NASDAQ OTIC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018N/AView Earnings Details
3/8/2018Q4 2017($0.67)($0.62)$0.46 million$0.27 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.84)($0.69)$0.43 million$0.28 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.80)($0.77)$0.43 million$0.33 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.8420)($0.89)$0.50 million$0.36 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.93)($0.88)$0.49 million$0.27 millionViewListenView Earnings Details
11/3/2016Q3 2016($0.98)($0.91)$0.23 million$0.32 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.93)($0.98)$1.60 million$0.08 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.85)($0.91)$0.80 million$0.01 millionViewN/AView Earnings Details
3/7/2016Q4($0.95)($0.87)ViewListenView Earnings Details
11/10/2015Q315($0.83)($0.57)ViewN/AView Earnings Details
8/12/2015Q116($0.67)($0.52)ViewN/AView Earnings Details
5/12/2015Q115($0.53)($0.52)ViewN/AView Earnings Details
3/18/2015Q415($0.64)($0.46)ViewListenView Earnings Details
11/12/2014Q3 2014($0.66)($1.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Otonomy (NASDAQ:OTIC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Otonomy (NASDAQ OTIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.70%
Institutional Ownership Percentage: 71.62%
Insider Trading History for Otonomy (NASDAQ:OTIC)
Institutional Ownership by Quarter for Otonomy (NASDAQ:OTIC)

Otonomy (NASDAQ OTIC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/26/2017Eric J. LoumeauInsiderSell3,522$18.59$65,473.98View SEC Filing  
11/21/2016Carl LebelInsiderSell10,625$18.07$191,993.7513,001View SEC Filing  
12/21/2015Carl LebelinsiderSell21,250$28.04$595,850.008,920View SEC Filing  
12/17/2015Paul E. CayerinsiderSell3,000$29.70$89,100.009,610View SEC Filing  
12/15/2015David Allen WeberCEOSell5,208$27.25$141,918.0017,603View SEC Filing  
12/14/2015Robert Michael Savel IIinsiderSell5,000$26.00$130,000.001,256View SEC Filing  
11/30/2015Chau Quang KhuongDirectorSell67,106$28.93$1,941,376.58View SEC Filing  
11/24/2015Orbimed Advisors LlcDirectorSell200,800$28.56$5,734,848.00View SEC Filing  
11/19/2015Chau Quang KhuongDirectorSell138,398$28.62$3,960,950.76View SEC Filing  
11/17/2015Paul E. CayerinsiderSell3,000$28.69$86,070.009,610View SEC Filing  
11/16/2015David Allen WeberCEOSell5,208$28.57$148,792.5617,603View SEC Filing  
11/13/2015David Allen WeberCEOSell10,416$30.95$322,375.20539View SEC Filing  
11/11/2015David Allen WeberCEOSell5,208$24.95$129,939.60539View SEC Filing  
11/11/2015Paul E. CayerCFOSell3,000$24.95$74,850.009,610View SEC Filing  
9/21/2015Carl LebelinsiderSell21,250$24.36$517,650.008,920View SEC Filing  
9/17/2015Paul E. CayerCFOSell3,000$24.95$74,850.009,610View SEC Filing  
9/15/2015David Allen WeberCEOSell5,216$24.95$130,139.20539View SEC Filing  
9/14/2015Robert Michael Savel IIinsiderSell5,000$23.98$119,900.001,256View SEC Filing  
6/15/2015Robert Michael Savel IIInsiderSell25,000$23.73$593,250.00View SEC Filing  
8/19/2014A/S NovoInsiderBuy15,690$15.50$243,195.00View SEC Filing  
8/18/2014A/S NovoInsiderBuy171,875$16.00$2,750,000.00View SEC Filing  
8/18/2014Jay LichterDirectorSell50,001$16.00$800,016.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Otonomy (NASDAQ OTIC) News Headlines

Source:
DateHeadline
Otonomy (OTIC) Upgraded to "Hold" by Zacks Investment ResearchOtonomy (OTIC) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:43 PM
Otonomy (OTIC) Upgraded by Zacks Investment Research to "Buy"Otonomy (OTIC) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 14 at 7:25 AM
Zacks Investment Research Lowers Otonomy (OTIC) to HoldZacks Investment Research Lowers Otonomy (OTIC) to Hold
www.americanbankingnews.com - April 13 at 8:29 AM
Otonomy (OTIC) Given Consensus Rating of "Hold" by AnalystsOtonomy (OTIC) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 13 at 1:41 AM
Acacia Pharma Expands US Commercial Operations for BAREMSIS® with Four Key AppointmentsAcacia Pharma Expands US Commercial Operations for BAREMSIS® with Four Key Appointments
globenewswire.com - April 11 at 5:31 PM
Otonomy (OTIC) Sees Hammer Chart Pattern: Time to Buy?Otonomy (OTIC) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 9 at 5:21 PM
Otonomy (OTIC) Upgraded to Buy by Zacks Investment ResearchOtonomy (OTIC) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:36 AM
Otonomy (OTIC) Downgraded by Zacks Investment ResearchOtonomy (OTIC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 10:48 AM
Otonomy (OTIC) Stock Rating Upgraded by Zacks Investment ResearchOtonomy (OTIC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:06 AM
Otonomy (OTIC) Stock Rating Lowered by Zacks Investment ResearchOtonomy (OTIC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:23 PM
Otonomy (OTIC) Upgraded by Zacks Investment Research to BuyOtonomy (OTIC) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 24 at 12:20 PM
JPMorgan Chase & Co. Lowers Otonomy (OTIC) to UnderweightJPMorgan Chase & Co. Lowers Otonomy (OTIC) to Underweight
www.americanbankingnews.com - March 19 at 10:58 AM
Otonomy Inc (OTIC) Given Average Rating of "Hold" by BrokeragesOtonomy Inc (OTIC) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 19 at 1:53 AM
Otonomy (OTIC) Upgraded to "Buy" by Zacks Investment ResearchOtonomy (OTIC) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 17 at 7:48 PM
Zacks Investment Research Downgrades Otonomy (OTIC) to HoldZacks Investment Research Downgrades Otonomy (OTIC) to Hold
www.americanbankingnews.com - March 17 at 12:04 PM
Otonomy (OTIC) Upgraded by Piper Jaffray Companies to "Overweight"Otonomy (OTIC) Upgraded by Piper Jaffray Companies to "Overweight"
www.americanbankingnews.com - March 12 at 2:21 PM
Frequency Therapeutics Welcomes Former Otonomy CSO as Executive Vice President of Clinical DevelopmentFrequency Therapeutics Welcomes Former Otonomy CSO as Executive Vice President of Clinical Development
www.bizjournals.com - March 12 at 9:16 AM
Otonomy, Inc. to Host Earnings CallOtonomy, Inc. to Host Earnings Call
finance.yahoo.com - March 9 at 6:49 PM
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateOtonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 9 at 6:49 PM
Otonomys (OTIC) CEO David Weber on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaOtonomy's (OTIC) CEO David Weber on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:21 AM
Otonomy (OTIC) Releases  Earnings ResultsOtonomy (OTIC) Releases Earnings Results
www.americanbankingnews.com - March 8 at 9:16 PM
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
www.globenewswire.com - March 8 at 6:42 PM
Bogle Investment Management L P DE Takes Position in Otonomy Inc (OTIC)Bogle Investment Management L P DE Takes Position in Otonomy Inc (OTIC)
www.americanbankingnews.com - March 5 at 5:10 AM
Hudson Bay Capital Management LP Has $1.11 Million Holdings in Otonomy Inc (OTIC)Hudson Bay Capital Management LP Has $1.11 Million Holdings in Otonomy Inc (OTIC)
www.americanbankingnews.com - March 3 at 12:50 PM
Otonomy (OTIC) Announces FDA Approval of OTIPRIO for Acute ... - StreetInsider.comOtonomy (OTIC) Announces FDA Approval of OTIPRIO for Acute ... - StreetInsider.com
www.streetinsider.com - March 3 at 8:17 AM
Otonomy (OTIC) Announces FDA Approval of OTIPRIO for Acute Otitis ExternaOtonomy (OTIC) Announces FDA Approval of OTIPRIO for Acute Otitis Externa
www.streetinsider.com - March 2 at 6:09 PM
Noteworthy Thursday Option Activity: ILG, OTIC, DERM - NasdaqNoteworthy Thursday Option Activity: ILG, OTIC, DERM - Nasdaq
www.nasdaq.com - March 2 at 8:17 AM
March PDUFA Dates: Mark Your Calendar, Biotech Investors (OTIC ... - BenzingaMarch PDUFA Dates: Mark Your Calendar, Biotech Investors (OTIC ... - Benzinga
www.benzinga.com - March 1 at 8:15 AM
Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update - GlobeNewswire (press release)Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:15 AM
PDUFA Watch List For March 2018 - Highlights For Amgen, Bristol-Myers, And Otonomy - Seeking AlphaPDUFA Watch List For March 2018 - Highlights For Amgen, Bristol-Myers, And Otonomy - Seeking Alpha
seekingalpha.com - March 1 at 8:15 AM
Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate UpdateOtonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - March 1 at 8:15 AM
Otonomy Inc (OTIC) Stake Increased by DLD Asset Management LPOtonomy Inc (OTIC) Stake Increased by DLD Asset Management LP
www.americanbankingnews.com - February 27 at 3:10 PM
 Brokerages Anticipate Otonomy Inc (OTIC) Will Announce Quarterly Sales of $250,000.00 Brokerages Anticipate Otonomy Inc (OTIC) Will Announce Quarterly Sales of $250,000.00
www.americanbankingnews.com - February 24 at 9:54 AM
Zacks: Brokerages Anticipate Otonomy Inc (OTIC) Will Announce Earnings of -$0.67 Per ShareZacks: Brokerages Anticipate Otonomy Inc (OTIC) Will Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - February 22 at 3:14 AM
Otonomy Inc (OTIC) Given Consensus Rating of "Hold" by BrokeragesOtonomy Inc (OTIC) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 22 at 1:24 AM
Otonomy Inc (NASDAQ:OTIC): Financial Strength AnalysisOtonomy Inc (NASDAQ:OTIC): Financial Strength Analysis
finance.yahoo.com - February 9 at 3:55 PM
Zacks: Analysts Anticipate Otonomy Inc (OTIC) Will Post Quarterly Sales of $250,000.00Zacks: Analysts Anticipate Otonomy Inc (OTIC) Will Post Quarterly Sales of $250,000.00
www.americanbankingnews.com - February 7 at 9:42 AM
Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology MeetingOtonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology Meeting
finance.yahoo.com - February 6 at 9:33 AM
Otonomy Inc (OTIC) Expected to Post Earnings of -$0.67 Per ShareOtonomy Inc (OTIC) Expected to Post Earnings of -$0.67 Per Share
www.americanbankingnews.com - February 5 at 3:12 AM
Otonomy (OTIC) Upgraded by Zacks Investment Research to "Hold"Otonomy (OTIC) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 31 at 6:46 AM
Whats Happening With These Biotech Stocks? -- Novavax, Opko Health, Otonomy, and Puma BiotechWhat's Happening With These Biotech Stocks? -- Novavax, Opko Health, Otonomy, and Puma Biotech
www.bizjournals.com - January 26 at 9:18 AM
$250,000.00 in Sales Expected for Otonomy Inc (OTIC) This Quarter$250,000.00 in Sales Expected for Otonomy Inc (OTIC) This Quarter
www.americanbankingnews.com - January 21 at 8:48 AM
Otonomy (OTIC) Downgraded by Zacks Investment Research to "Sell"Otonomy (OTIC) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - January 17 at 9:18 AM
Otonomy Provides Corporate and Product Pipeline UpdateOtonomy Provides Corporate and Product Pipeline Update
finance.yahoo.com - January 9 at 10:07 AM
Otonomy to Present at the J.P. Morgan Healthcare ConferenceOtonomy to Present at the J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 10:06 AM
ETFs with exposure to Otonomy, Inc. : December 28, 2017ETFs with exposure to Otonomy, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:39 PM
Otonomy, Inc. :OTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Otonomy, Inc. :OTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 2:39 PM
Otonomy, Inc. (OTIC) Expected to Announce Quarterly Sales of $250,000.00Otonomy, Inc. (OTIC) Expected to Announce Quarterly Sales of $250,000.00
www.americanbankingnews.com - December 18 at 4:16 PM
Otonomy, Inc. (OTIC) Receives Consensus Rating of "Hold" from AnalystsOtonomy, Inc. (OTIC) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 9 at 1:48 AM
Otonomy, Inc. to Post Q4 2017 Earnings of ($0.75) Per Share, SunTrust Banks Forecasts (OTIC)Otonomy, Inc. to Post Q4 2017 Earnings of ($0.75) Per Share, SunTrust Banks Forecasts (OTIC)
www.americanbankingnews.com - December 1 at 3:52 PM

SEC Filings

Otonomy (NASDAQ:OTIC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Otonomy (NASDAQ:OTIC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Otonomy (NASDAQ OTIC) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.